Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)

26 de setembro de 2017 atualizado por: Francine K. Welty, Beth Israel Deaconess Medical Center

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)

The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Study Design: This is a randomized, parallel study design with a usual care control group. 278 subjects with coronary heart disease (CHD) are being randomized to omega-3 supplementation or standard of care (139 in each arm).

Multidetector computed tomographic angiography (MDCTA) is performed at baseline to quantitate the amount of noncalcified and calcified coronary plaque and again at 30 month follow-up to determine if there has been a change in the volume of noncalcified or total plaque. The primary endpoint is change in coronary noncalcified plaque volume during the 30 months of intervention between active and standard of care.

Hypothesis: Percent change in progression of coronary plaque volume will be less for the omega-3 fatty acid intervention compared to standard of care.

Secondary endpoints include plasma levels of inflammatory markers, lipids and measures of insulin sensitivity.

Secondary outcomes include testing the hypothesis that targeting inflammation with omega-3 fatty acids will be associated with:

  1. Change in total plaque volume per patient.
  2. improvement in physical function and exercise and reduction in pain and stiffness as measured by the WOMAC questionnaire
  3. Reduction of mediators of inflammation in the circulation including CRP, PAI-1, serum amyloid A, MMP-9 and fibrinogen, pro-inflammatory cytokines including IL-6, TNF-a and IL-1b, the adhesion molecules VCAM-1 and ICAM-1, increase in adiponectin and reduction in serum nitrotyrosine as a marker of oxidative stress.
  4. Reduction of insulin resistance assessed by fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR).
  5. Reduction of inflammation in the liver associated with nonalcoholic steatohepatitis (NASH), a newly recognized component of the metabolic syndrome, and reduction of fatty liver quantitated by computerized tomography and levels of AST and ALT as markers of liver inflammation related to NASH.
  6. Investigation of the relationship between vitamin D status and coronary plaque progression as well as with insulin resistance (HOMA-IR), beta-cell function (HOMA-%beta) and inflammatory cytokines.
  7. Determination of whether baseline vitamin D levels predict clinical response to the omega-3 fatty acid intervention, and whether hypovitaminosis D is associated with plaque progression.

Tipo de estudo

Intervencional

Inscrição (Real)

338

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Beth Israel Deaconess Medical Center
      • Milton, Massachusetts, Estados Unidos, 02186
        • South Shore Medical Group

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. coronary artery disease
  2. previous myocardial infarction
  3. angioplasty (> 6 months ago)
  4. previous coronary bypass surgery (> 12 months ago)
  5. stable angina
  6. non-calcified plaque on prior CT
  7. abnormal exercise tolerance test
  8. aged 21- 80 years
  9. BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI > 24.5 for subjects from Asian origin)
  10. stable dose of statin for 1 month at screening or unable to tolerate a statin
  11. normal renal function - estimated creatinine clearance calculated using Cockcroft-Gault (CG) equation ≥60 at screening [eCrCLCG (ml/min) = [(140 - age) x weight (kg)]/[SCr(mg/dl) x 72] x [0.85 if female] or serum Cr < 1.3
  12. ALT, AST) < 3 times upper limits of normal)
  13. normal thyroid function or on stable dose replacement therapy
  14. an ETT performed within 12 months prior

Exclusion criteria

  1. unstable angina (increase in frequency or severity of anginal episodes or development of chest pain at rest)
  2. significant obstructive disease in left main coronary artery, ostial LAD or newly diagnosed three-vessel disease since prior cardiac catheterization by MDCTA
  3. significant heart failure (NYHA class III and IV)
  4. Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome
  5. allergy to beta-blocker in subjects with resting heart rate > 65 bpm
  6. systolic blood pressure > 160 mm Hg
  7. diastolic BP > 100 mm Hg
  8. persons with allergies to iodinated contrast material or shellfish
  9. allergy to nitroglycerin
  10. history of asthma only if unable to tolerate beta-blockers
  11. BMI > 35 kg/m2 if female and > 40 kg/m2 if male
  12. body weight > 350 lbs
  13. Use of drugs for weight loss [eg Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the-counter medications] within three months of screening
  14. surgery within 30 days of screening
  15. history of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
  16. poor mental function or history of dementia/Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)] or any other reason to except patient difficulty in complying with the requirements of the study
  17. medicine for erectile dysfunction within 72 hours prior to MDCTA
  18. Prior stroke with residual cognitive deficit or functional deficit preventing any type of exercise
  19. Current chemotherapy or radiation for malignancy
  20. Current weekly alcohol consumption > 21 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)

Exclusions based on nuclear imaging:

  1. Transient cavity dilation
  2. More than one vascular territory involved with reversible defect (multiple defects)
  3. Reversible defects involving the anterior wall, septum or apex (LAD territory)

Exclusions based on echocardiography imaging:

1. More than one vascular territory involved with inducible wall motion abnormalities (multiple defects) 2. Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD territory)

-

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Usual care
Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
Comparador Ativo: Lovaza (Omega 3 ethyl esters)
Suplemento dietético: Omega 3 acid ethyl esters
Lovaza 3.6 g daily

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
The primary endpoint is change in coronary noncalcified plaque volume.
Prazo: Baseline and 30 months
MDCTA is performed at baseline to quantitate the amount of noncalcified and calcified coronary plaque and again at 30 month follow-up to determine if there has been a change in the volume of noncalcified or total plaque. The primary endpoint is change in coronary noncalcified plaque volume during the 30 months of intervention between active and standard of care. The hypothesis is that those on Lovaza will have less progression of coronary plaque compared to those in usual care.
Baseline and 30 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Coronary artery plaque assessment
Prazo: Baseline and 30 months
  1. Percent atheroma volume calculated as the proportion of the entire vessel wall occupied by atherosclerotic plaque and total atheroma volume, normalized to segment length.
  2. Maximum percent diameter stenosis and minimal luminal diameter.
  3. Number of subjects with categorical variables of maximal stenosis >50% and number with 3-vessel disease >20%.
  4. Number of subjects with stenosis of 0-29%, 30-49%, 50-69% and >70% stenosis at baseline compared to 30 months.
  5. Change in remodeling index - ratio of plaque volume at the most diseased site compared to the least diseased site.
Baseline and 30 months
Effect of Lovaza on Physical Function, Pain, Stiffness and Exercise
Prazo: Baseline and 1 year
Those on Lovaza will have better physical function and less pain and stiffness as assessed by the WOMAC questionnaire and more minutes of exercise per week compared to control
Baseline and 1 year
Inflammatory markers
Prazo: Baseline and 30 months
Compared to usual care, those on Lovaza will have reduction of mediators of inflammation in the circulation, including CRP, PAI-1, serum amyloid A, MMP-9 and fibrinogen, pro-inflammatory cytokines including IL-6, TNF-a and IL-1b, the adhesion molecules VCAM-1 and ICAM-1, increase in adiponectin and reduction in serum nitrotyrosine as a marker of oxidative stress. Additional inflammatory markers may be identified in the future and measured.
Baseline and 30 months
Pericardial Fat
Prazo: Baseline and 30 months
The amount of pericardial fat will be quantitated by CT at baseline and 30-month follow-up. The percent change between the two time-frames will be measured. Those on Lovaza and/or those who have lost weight will have a reduction (or lack of increase) in pericardial fat at 30-months compared to those in usual care.
Baseline and 30 months
Insulin Resistance
Prazo: Baseline and 30 months
Insulin resistance will be assessed by fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) at baseline and 30-months in the two study groups.
Baseline and 30 months
Nonalcoholic steatohepatitis (NASH)
Prazo: Baseline and 30 months
Reduction of inflammation in the liver associated with nonalcoholic steatohepatitis (NASH), a component of the metabolic syndrome, and reduction of fatty liver quantitated by computerized tomography and levels of AST and ALT as markers of liver inflammation related to NASH.
Baseline and 30 months
Vitamin D Levels and coronary plaque progression
Prazo: Baseline and 30 months
  1. Investigation of the relationship between vitamin D status and coronary plaque progression, insulin resistance (HOMA-IR), beta-cell function (HOMA-%beta) and inflammatory cytokines
  2. Do baseline vitamin D levels predict response to omega-3 fatty acid supplementation?
Baseline and 30 months
Cognitive function
Prazo: Baseline, 1 year and 30-months
To determine if those on Lovaza have less decline in cognitive function at 1 year and 30 months of follow-up compared to those in the usual care group.
Baseline, 1 year and 30-months
Exercise capacity and coronary plaque
Prazo: Baseline
To determine if exercise capacity correlates with coronary plaque measurements. The hypothesis is that those with better exercise capacity will have lower amounts of coronary plaque.
Baseline
Urinary microalbumin and coronary plaque
Prazo: Baseline and 30-months
At baseline, subjects with lower urinary microalbumin will have lower amounts of coronary plaque. Those taking Lovaza will have less increase in urinary microalbmumin at 30-month follow-up compared to those in usual care.
Baseline and 30-months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Beth Israel Deaconess Medical Center

Colaboradores

National Heart, Lung, and Blood Institute (NHLBI)
Tufts Medical Center

Investigadores

  • Investigador principal: Francine K Welty, MD, PhD, Beth Israel Deaconess Medical Center

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de junho de 2009

Conclusão Primária (Real)

15 de janeiro de 2015

Conclusão do estudo (Real)

15 de janeiro de 2015

Datas de inscrição no estudo

Enviado pela primeira vez

15 de maio de 2012

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de junho de 2012

Primeira postagem (Estimativa)

21 de junho de 2012

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de setembro de 2017

Última atualização enviada que atendeu aos critérios de controle de qualidade

26 de setembro de 2017

Última verificação

1 de setembro de 2017

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • 2006P000175
  • P50HL083813 (NIH)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever